Name: systemic delivery of microrna using recombinant adeno-associated virus serotype 9 to treat neuromuscular diseases in rodents
Uploaded: 2018-08-10T12:30:00.000+00:00
Duration: 6 min 51 s
Description: Watch this Scientific Journal Video about Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents at JoVE.com

作者声明没有利益冲突。我们感谢 SignaGen 实验室 (Rockvile, 美国 MD) 为 AAV9 病毒生产。这项研究得到了 NINDS 的校内研究计划的支持。菲利普 r. 李得到了发育研究院校内研究司的资金支持。卡洛雷那蒂得到了来自协会法国反肌病 (AFM) 的奖学金的支持。

所有程序都是按照国家卫生研究院的护理和使用实验动物指南 (第八, 国家科学院出版社, 修订 2011) 进行的, 并已得到 NINDS 动物护理委员会的批准。
1. AAV9-miRNA 设计策略和 miRNA 选择
<ol><li>使用 miRWalk 预测数据库选择与目标基因的 mRNA 3 ' UTR 区域交互的候选 miRNAs。15 注: 将 miRNA 序列的最小种子长度限制在至少7核苷酸上。选择其他已建立的 miRNA 预测计划 (米兰达, miRDB, Targetscan) 进行比较分析。根据这些选择标准, 本文选择了 miR-185、miR-298、miR-873 和 miR-877 进行进一步的评价。</li>
	<li>从 miRBase (http://www.mirbase.org/) 中检索选定 miRNA 的序列。</li>
	<li>将和平号 (60-70) 和其250-300 个侧翼的基因组序列复制到相应的 AAV cis 向量中, 或模拟序列。 注意: 侧翼序列是正确的和平号表达和成熟的 microRNA 处理所必需的。选择一个双启动子 rAAV cis 向量, 其表达式盒包括人体伸长 factor-1 alpha (EIF1α) 启动子, 后跟选定的 miRNA 或模拟序列, 以及人巨细胞病毒 (CMV) 启动子和 cDNA 编码GFP 荧光标记。选择 EIFα启动子是因为它保证了稳定和均匀的表达, 沉默的风险最小。根据特定的应用, 可以使用组织特定的或有条件的启动子。</li>
	<li>根据已发布的协议, 准备、纯化和滴定 AAV。16 注: 在这里, 克隆的和平号到 AAV 的载体和病毒的生产是由外部制造商执行。</li>
</ol>2. AAV-miRNA 质粒的尾静脉注射
注意: 这一步需要根据目标基因和小鼠的年龄和体重进行调整。使用机构和动物护理和使用委员会 (IACUC) 指南, 以确定的剂量范围, 数量和最佳的管理途径, 根据年龄和体重的小鼠。GFP 荧光信号和 miRNA 在靶组织中的表达水平预计在注射后2周开始峰值。以下议定书是指成年早期雄性小鼠。在生物安全等级1准则下, AAV 应作为生化危害处理。
<ol><li>用无菌磷酸盐缓冲盐水 (PBS) 将 AAV-miRNA 质粒库存在100-200 µL 整除数中, 含有 1010-1011病毒基因组的病毒载量 (vg/毫升)。实验室生物危害个人防护设备应用于处理 AAV 解决方案。 注: 一旦整除解冻, 它可以保存在4摄氏度, 长达两周。病毒的股票可以储存在-80 °c 冰箱。</li>
	<li>在商用抑制剂中抑制鼠标, 如塑料或锥形塑料膜管的适当尺寸。</li>
	<li>用70% 酒精湿巾清洁尾部表面。</li>
	<li>在尾部下保持一个温暖的垫 (28-30 °c), 以增加三十年代的血管舒张. 或者, 用一盏红色的灯 (在2-3 英尺的距离) 或将尾部浸入温水中来加热动物。</li>
	<li>
从尾部的远端部分开始, 插入针 (27-30 克) 载有病毒的整除, 斜面向上, 从尾部, 从尾, 到静脉。注射前, 确保针正确插入。
	<ol>
<li>如果在注射过程中感觉到阻力, 或者皮肤肿胀出现, 停止手术。取出针头, 再将针插入上一个注射点上方。 注: 另外, 这可以通过轻轻地吸针和观察血液来实现。坚硬的吸入可以折叠尾脉。如果静脉在注射过程中 blanches, 针插入正确。</li>
	</ol>
</li>
	<li>注射完成后, 在抬针前等几秒钟。</li>
	<li>观察注射部位出血。使用两个手指的适度压力到现场, 直到出血停止。</li>
	<li>把动物送到笼子里去。</li>
</ol>3. 行为化验
注: 所有实验都是由第三方盲目进行的, 用独特的编码小瓶掩盖治疗方法。治疗顺序是随机的。在执行下面描述的测试时, 应控制实验条件 (房间和时间的类型), 以减少变化。本试验应在四周以上的小鼠身上进行, 以达到可靠的效果。小鼠在5周的病毒注射前进行过一次行为评估, 以获得正常表现的基线。病毒注射后, 每周一次对小鼠进行一次48小时的注射, 达到40周的年龄。
<ol><li>将鼠标注入 AAV 到一个安静的, 黑暗的房间, 没有噪音或其他干扰至少30分钟, 然后开始测试。在这种驯化期间不要打扰动物。</li>
	<li>将鼠标适应新房间30分钟, 然后开始以下行为检测 (步骤3.3 和 3.4)。在每种行为分析之间保持10分钟的差距。</li>
	<li>
挂线试验 注意: 这个测试监测肌肉力量和运动障碍。<ol>
<li>使用填充纸作为缓冲。拿起鼠标的尾巴, 并把它放在电线网架的中心。将机架抬高15-20 英寸以上的表面, 并慢慢反转屏幕, 让动物调整其在屏幕上的抓地力。</li>
		<li>一旦机架完全颠倒, 启动定时器, 并记录时间下降。 注意: 老鼠会在网格上挂上四只四肢。如果电线设置得太低, 老鼠可能不会挂上。如果老鼠在六十年代之前从网格上掉下来, 把它们放回到网格上, 重新设置定时器, 再重复这个过程最多再试两次。注册最佳性能。</li>
		<li>当达到六十年代的期限时, 把动物送回笼子。</li>
	</ol>
</li>
	<li>
足印检测 注: 吸水片应为一条狭窄的跑道, 长约70厘米, 宽5厘米, 5 厘米高的墙壁。<ol>
<li>用一只手轻轻握住鼠标, 用刷子将红色墨水涂在前爪和蓝色墨水上。</li>
		<li>把吸水纸放在狭窄跑道的地板上。</li>
		<li>允许鼠标在跑道上的一条直线上行走或奔跑, 从一端到其他。</li>
		<li>用新的吸水纸重复这一过程两次与鼠标。</li>
		<li>测量前进运动中连续两个步骤之间的距离。不要包括第一和最后几个脚印, 动物只是启动和完成它的运行。</li>
	</ol>
</li>
</ol>4. 安乐死和组织收获
<ol><li>使用安乐死室或钟罐。如果使用钟罐, 在通风罩下执行程序。</li>
	<li>用异氟醚浸泡棉花, 放在钟罐子里。使用物理分离器保持动物与麻醉材料的物理接触。在这一步之后立即将动物放在罐子里。 注: 钟罐不应预先充电与异氟醚, 以避免可能的低氧血症的动物。</li>
	<li>继续接触异氟醚, 直到三十年代呼吸停止。</li>
	<li>将鼠标从罐子中取出后立即弄死颈椎脱位。 注意: 这一步应尽可能快地进行, 以避免组织退化。</li>
	<li>
首先收获脊髓, 然后是四头肌骨骼肌。
	<ol>
<li>要收割脊髓, 露出老鼠的背面, 把四只四肢固定在解剖板上。</li>
		<li>用70% 乙醇清洗解剖部位。</li>
		<li>用锋利的剪刀做颈椎脱位。</li>
		<li>在正中线的皮肤上做一个切口。通过切割或仔细撕裂在横向平面上的皮肤, 然后拉的皮毛向上和头部的皮毛删除。用剪刀剪下肩胛骨, 在柱子的 C1-2 区域 (发现在头骨的基底附近) 切下头部。<ol>
<li>切开腹壁肌组织在腹侧和继续侧向, 一次方向, 直到脊柱被到达。</li>
		</ol>
</li>
		<li>用锋利的剪刀从颈椎脊髓开始切除椎骨。通过跨椎弓两侧切除椎骨的侧部。</li>
		<li>切除整个椎骨后释放脊髓。</li>
	</ol>
</li>
	<li>
用以下方法对预冷2丁烷中的收获组织进行冻结;
	<ol>
<li>半填充一个不锈钢碗与2丁烷和淹没底部季度的碗在一个充满液氮的容器。</li>
		<li>在液氮中预冷 2-丁烷1-2 分钟。</li>
		<li>将骨骼肌与钳在2丁烷, 直到它变成白色。立即将组织转移到干冰, 然后将其储存在-80 摄氏度。</li>
	</ol>
</li>
	<li>对于脊髓染色, 在凝固冰冻之前, 在室温下将组织嵌入石蜡块中。17
</li>
	<li>为了进行生化分析和 miRNA 定量,1将收获的组织 cryovial 在液氮中冷冻。把样品存放在摄氏-80 摄氏度。</li>
</ol>

<ol>
	<li>Broderick, J. A., Zamore, P. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=miRNA+therapeutics.">miRNA therapeutics.</a> Gene Therapy. 18, 1104-1110 (2011).</li><li>Esteller, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Non-coding+RNAs+in+human+disease.">Non-coding RNAs in human disease.</a> Nat Rev Genet. 12, 861-874 (2011).</li><li>Pickering, B. M., Willis, A. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+implications+of+structured+5'+untranslated+regions+on+translation+and+disease.">The implications of structured 5' untranslated regions on translation and disease.</a> Semin Cell Dev Biol. 16, 39-47 (2005).</li><li>Bilen, J., Liu, N., Burnett, B. G., Pittman, R. N., Bonini, N. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=MicroRNA+pathways+modulate+polyglutamine-induced+neurodegeneration.">MicroRNA pathways modulate polyglutamine-induced neurodegeneration.</a> Mol Cell. 24, 157-163 (2006).</li><li>Lee, Y., Samaco, R. C., Gatchel, J. R., Thaller, C., Orr, H. T., Zoghbi, H. Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=miR-19,+miR-101+and+miR-130+co-regulate+ATXN1+levels+to+potentially+modulate+SCA1+pathogenesis.">miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis.</a> Nat Neurosci. 11, 1137-1139 (2008).</li><li>Liu, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+microRNA+miR-34+modulates+ageing+and+neurodegeneration+in+Drosophila.">The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila.</a> Nature. 482, 519-523 (2012).</li><li>Ebner, D. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Strategies+for+skeletal+muscle+targeting+in+drug+discovery.">Strategies for skeletal muscle targeting in drug discovery.</a> Curr Pharm Des. 10, 1327-1336 (2015).</li><li>Giorgetti, E., Lieberman, A. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Polyglutamine+androgen+receptor-mediated+neuromuscular+disease.">Polyglutamine androgen receptor-mediated neuromuscular disease.</a> Cell Mol Life Sci. 73, 3991-3999 (2016).</li><li>Grunseich, C., Rinaldi, C., Fischbeck, K. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Spinal+and+bulbar+muscular+atrophy:+pathogenesis+and+clinical+management.">Spinal and bulbar muscular atrophy: pathogenesis and clinical management.</a> Oral Dis. 20, 6-9 (2014).</li><li>La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E., Fischbeck, K. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Androgen+receptor+gene+mutations+in+X-linked+spinal+and+bulbar+muscular+atrophy.">Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.</a> Nature. 352, 77-79 (1991).</li><li>Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M., Sobue, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Testosterone+reduction+prevents+phenotypic+expression+in+a+transgenic+mouse+model+of+spinal+and+bulbar+muscular+atrophy.">Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.</a> Neuron. 35, 843-854 (2002).</li><li>Boissonneault, V., Plante, I., Rivest, S., Provost, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=MicroRNA-298+and+microRNA-328+regulate+expression+of+mouse+beta-amyloid+precursor+protein-converting+enzyme+1.">MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.</a> J Biol Chem. 284, 1971-1981 (2009).</li><li>Choudhury, S. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Widespread+central+nervous+system+gene+transfer+and+silencing+after+systemic+delivery+of+novel+AAV-AS+vector.">Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector.</a> Mol Ther. 24, 726-735 (2016).</li><li>Pourshafie, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=MiR-298+counteracts+mutant+androgen+receptor+toxicity+in+spinal+and+bulbar+muscular+atrophy.">MiR-298 counteracts mutant androgen receptor toxicity in spinal and bulbar muscular atrophy.</a> Mol Ther. 24, 937-945 (2016).</li><li>Dweep, H., Sticht, C., Pandey, P., Gretz, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=miRWalk--database:+prediction+of+possible+miRNA+binding+sites+by+&amp;#34;walking&amp;#34;+the+genes+of+three+genomes.">miRWalk--database: prediction of possible miRNA binding sites by &amp;#34;walking&amp;#34; the genes of three genomes.</a> J Biomed Inform. 44, 839-847 (2011).</li><li>McClure, C., Cole, K. L., Wulff, P., Klugmann, M., Murray, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Production+and+titering+of+recombinant+adeno-associated+viral+vectors.">Production and titering of recombinant adeno-associated viral vectors.</a> J Vis Exp. (57), e3348 (2011).</li><li>Stuard, D. A., Oorschot, D. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Embedding,+sectioning,+immunocytochemical+and+stereological+methods+that+optimise+research+on+the+lesioned+adult+rat+spinal+cord.">Embedding, sectioning, immunocytochemical and stereological methods that optimise research on the lesioned adult rat spinal cord.</a> J Neurosci Methods. 61, 5-14 (1995).</li><li>Huang, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=miR-25+alleviates+polyQ-mediated+cytotoxicity+by+silencing+ATXN3.">miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3.</a> FEBS Lett. 588, 4791-4798 (2014).</li><li>Kuhn, D. E., Martin, M. M., Feldman, D. S., Terry, A. V., Nuovo, G. J., Elton, T. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Experimental+validation+of+miRNA+targets.">Experimental validation of miRNA targets.</a> Methods. 44, 47-54 (2008).</li><li>Yang, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+overview+of+viral+and+nonviral+delivery+systems+for+microRNA.">An overview of viral and nonviral delivery systems for microRNA.</a> Int J Pharm Investig. 5, 179-181 (2015).</li><li>Bourdenx, M., Dutheil, N., Bezard, E., Dehay, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Systemic+gene+delivery+to+the+central+nervous+system+using+Adeno-associated+virus.">Systemic gene delivery to the central nervous system using Adeno-associated virus.</a> Front Mol Neurosci. 7, 50 (2014).</li><li>Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., Kaspar, B. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intravascular+AAV9+preferentially+targets+neonatal+neurons+and+adult+astrocytes.">Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.</a> Nat Biotechnol. 27, 59-65 (2009).</li><li>Wang, Z., Ma, H. -. I., Li, J., Sun, L., Zhang, J., Xiao, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rapid+and+highly+efficient+transduction+by+double-stranded+adeno-associated+virus+vectors+in+vitro+and+in+vivo.">Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.</a> Gene Therapy. 10, 2105-2111 (2003).</li><li>Saunders, N. R., Joakim Ek, C., Dziegielewska, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+neonatal+blood-brain+barrier+is+functionally+effective,+and+immaturity+does+not+explain+differential+targeting+of+AAV9.">The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9.</a> Nat Biotechnol. 27, 804-805 (2009).</li><li>Boudreau, R. L., Spengler, R. M., Davidson, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rational+design+of+therapeutic+siRNAs:+minimizing+off-targeting+potential+to+improve+the+safety+of+RNAi+therapy+for+Huntington&#8217;s+disease.">Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington&#8217;s disease.</a> Mol Ther. 19, 2169-2177 (2011).</li><li>Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intravenous+administration+of+self-complementary+AAV9+enables+transgene+delivery+to+adult+motor+neurons.">Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.</a> Mol Ther. 17, 1187-1196 (2009).</li><li>Lowenstein, P. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Crossing+the+rubicon.">Crossing the rubicon.</a> Nat Biotechnol. 27, 42-44 (2009).</li><li>Sibley, C. R., Seow, Y., Curtis, H., Weinberg, M. S., Wood, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Silencing+of+Parkinson's+disease-associated+genes+with+artificial+mirtron+mimics+of+miR-1224.">Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224.</a> Nucleic Acids Res. 40, 9863-9875 (2012).</li></ol>

作者没有什么可透露的。

在这里, 我们展示了一个高效和可访问的方法来选择和提供通过尾部注射 miRNA 使用 rAAV9 作为一个病毒载体的目标骨骼肌和运动神经元的小鼠。14与其他 rna 干扰策略相比, miRNAs 毒性较小, 免疫少。18此外, 它们的小尺寸使它们很适合病毒载体的有限包装能力。2计算算法和预测工具允许识别假定的 miRNA mRNA 目标。一旦确定, miRNA 对靶基因表达的影响必须得到验证。一种常见的方法是在体外过度表达 tshr 一个给定的 miRNA, 并利用西方的分析来检测目标蛋白的表达水平。14,19
各种研究已经使用病毒和非病毒的策略来提供 miRNAs。13在这里, 我们用腺相关病毒 (AAV) 作为基因传递工具。与其他病毒载体相比, AAV 诱导低免疫原性, 允许长期基因转移, 在分裂和非分裂细胞中具有广泛的取向。18这种传递方法还可以规避对化学修饰的需要, 这可能会影响 RNA 分子的功能和特异性。AAV 有几种血清型, 主要由衣壳蛋白组成。这些血清型不同于它们的取向和传感器不同的细胞类型。在考虑靶组织时, 有必要选择正确的血清型。我们选择 rAAV9, 由于其在中枢神经系统和骨骼肌的高转导效率19,20。这种方法显示, 与成年动物相比, 新生动物的转导效果更大, 可能是由于细胞外基质成分的差异、神经元与神经胶质的比值以及血脑屏障的成熟。21,22
该协议的一个重要步骤是表达式向量的设计。与 bicistronic 载体相比, 由于第二基因的表达低于启动子旁边的第一个基因而受到阻碍, 因此双启动子向量允许在 miRNA 和 EGFP 之间产生高表达的背对回配置, 从而允许免疫荧光 miRNA 在小鼠组织中的定位。
静脉注射 AAV9 导致靶组织、骨骼肌和运动神经元的高效和均匀传导。这一注射途径允许被管理的剂量达到系统循环和跨脑血屏障, 这对于针对中枢神经系统的治疗非常重要。此外, 它是一种非侵入性的方法交付中枢神经系统。MiR-298 表达在脊髓和肌肉中增加2-4 周后, 单个外周注射在5周的年龄。在使用单链基因组 AAV 载体时, 第二 DNA 链的从头合成可以解释延迟转导。23
在治疗小鼠20周后, 一个单一的管理, 人类 miR-298 的水平是无法检测的, 这表明对于慢性病, 可能需要多次注射才能达到治疗效果。然而, 随着时间的推移, miRNA 的退化可能会限制在需要终生重复管理的情况下。此外, 对 AAV 载体的自适应免疫可以成为成功基因传递的另一个障碍。24因而免疫惰性的世代 AAV 媒介是关键的对重复的管理和达到长期作用以这个有希望的运载系统。25
对使用 miRNA 作为治疗策略的限制是非靶向效应的风险。MiRNAs 可以通过 incomplementary 基础配对与其他基因转录, 这构成了安全风险的方法。改进的干扰序列的设计, 包括使用非规范的 miRNAs, 如 mirtrons, 绕过微处理器复杂和广泛的长期安全和耐受性研究是至关重要的, 然后将此策略转换为安全和有效的治疗方法。26,27,28
本文所描述的方法最初是为 miRNA 过度表达而开发的, 但也可用于 miRNA 抑制治疗, 使用 antagomirs。

MiRNAs 是非编码 rna, 21-23 核苷酸长度, 在调控基因表达和控制不同的细胞和代谢通路方面起着重要作用。1基因表达主要通过诱导转录后基因沉默或 mRNA 降解来调节。2 MiRNAs 通常是互补的 3 ' 未翻译的区域 (UTR) 编码基因, 虽然绑定到 5 ' UTR 和编码区域的目标 mRNA 也被描述。3
由于目前对 miRNA 在人类疾病发病机制中的作用的理解不断扩大, 个体 miRNAs 或 miRNA 家庭的药理调控越来越成为一种可行的治疗方案。与其他 RNA 抑制策略相比, miRNAs 有许多优点: miRNAs 毒性较小, 免疫少, 而且由于体积小, 容易被送进细胞。4,5,6 MiRNAs 通常在蜂窝网络中有许多目标, 因此需要考虑潜在的非目标效应和安全问题, 同时有效地向目标组织提供。
神经肌肉疾病是获得或继承的条件, 影响肌肉和运动神经元。将药物定向到骨骼肌是一个新兴的研究领域, 主要的挑战是在治疗窗口内实现广泛的分布。7运动神经元的靶点比较困难, 主要是因为血液中的脑屏障排除了药物的进入。
本研究采用细胞培养和小鼠脊髓和球肌萎缩 (SBMA) 模型。SBMA 是一种神经肌肉疾病, 由功能机制的毒性增益引起, 其中肌肉和运动神经元都受到影响。8,9 SBMA (肯尼迪病;OMIM #313200) 是一种 X 关联的疾病, 其特点是肌肉虚弱和萎缩, 由 CAG 基因重复扩张引起的, 这对ar蛋白中的扩展 polyglutamine 道进行编码。10目前尚无治疗此病的疾病改良疗法。本研究使用的转基因小鼠模型概括了该病的特点, 包括性别特异性、运动神经元病理学和渐进性肌肉萎缩。11
在这项研究中, 我们的努力集中在确定一个 miRNA 直接 downregulates 的基因突变 AR 基因的表达和设计一个安全和有效的方式交付 miRNA 脊髓和骨骼肌肉的疾病小鼠模型。
在这里, 我们确定了一个相对 uncharacterized miRNA, miRNA-298 (加入编号 MIMAT0004901),12直接减少突变 AR 表达在 SBMA 模型。为了实现对靶组织的 miR-298, 我们采用了病毒策略, 重组腺相关病毒9型 (rAAV9)。rAAV9 能够跨越血脑屏障, 在非分裂细胞 (包括神经元) 中进行长期基因表达。13 AAV9-miR-298 的单一系统管理导致了 miRNA 的持续表达, 肌肉和运动神经元的有效传导, AR 表达的下降调节, 以及改善 SBMA 小鼠的疾病表型。14本方法可用于在体内提供 miRNA 或 antagomirs 过度表达。

<table><tbody><tr><td>QIAzol Lysis Reagent</td><td>Qiagen</td><td>79306</td><td>Lysis of fatty and standard tissues before RNA isolation</td></tr><tr><td>miRNeasy Mini Kit</td><td>Qiagen</td><td>217004</td><td>Purification of miRNA and total RNA</td></tr><tr><td>TaqMan MicroRNA Reverse Transcription kit</td><td>ThermoFisher Scientific</td><td>4366596</td><td>A highly specific kit that quantitates only mature miRNAs</td></tr><tr><td>snoRNA202 Primer</td><td>ThermoFisher Scientific</td><td>1232</td><td>Taqman miRNA control assay in mouse</td></tr><tr><td>miR-298 Primer</td><td>ThermoFisher Scientific</td><td>2190</td><td>Taqman miRNA-298 assay in mouse</td></tr><tr><td>Anti-GFP antibody</td><td>abcam</td><td>ab290</td><td>Rabbit polyclonal to GFP - ChIP Grade</td></tr><tr><td>Red ink pad</td><td>Dovecraft Essentials</td><td></td><td></td></tr><tr><td>Blue ink pad</td><td>Dovecraft Essentials</td><td></td><td></td></tr><tr><td>AAV9-GFP vector</td><td>SignaGen Laboratories</td><td>SL100840</td><td>Large scale AAV plasmid construction, packaging and purification</td></tr><tr><td>mmu-miR-298-5p</td><td>ThermoFisher Scientific</td><td>MC12525</td><td>mirVana miRNA mimic</td></tr><tr><td>AAV9-EF1a-has-mir-298-GFP</td><td>Vector Biosystems Inc</td><td></td><td></td></tr></tbody></table>

systemic delivery of microrna using recombinant adeno-associated virus serotype 9 to treat neuromuscular diseases in rodents

RNA 干扰通过内源 miRNA 通路调控基因表达通过控制蛋白质合成通过转录后基因沉默。近年来, miRNA 介导的基因调控已经显示了治疗神经疾病的潜能, 这是由功能机制的毒性增益引起的。然而, 有效地向目标组织传递却限制了它的应用。在这里, 我们使用了转基因小鼠模型脊髓和球肌萎缩 (SBMA), 一种神经肌肉疾病由 polyglutamine 扩张的雄激素受体 (AR), 以测试基因沉默的新确定的 AR 靶向 miRNA, miR-298。我们抗原 miR-298 使用重组腺相关病毒 (rAAV) 型9向量, 以促进非分裂细胞的转导。单尾静脉注射 SBMA 小鼠导致骨骼肌和运动神经元中 miR-298 的持续和广泛表达, 从而改善了小鼠神经肌肉表型。

1011 vg 的 AAV9-miR-298 的病毒负载通过一个单一的尾静脉注射注入5周老 SBMA 小鼠。这些小鼠在 ar (AR97Q) 中携带的人 ar 转基因与异常扩张的 polyglutamine, 并形成神经肌肉疾病的迹象10周的年龄 (体重减轻, 驼背背部和肌肉萎缩)。在 miRNA 定量化、生化测定和免疫组化 (图 12) 的管理后, 2、4、8和1周内收获11腰椎脊髓和四头肌。治疗的管理和随后的分析是由盲人调查员进行的。
qRT PCR 分析显示, 在治疗后两周和四周的骨骼肌和脊髓 miR-298 表达, 在骨骼肌8周的峰值表达水平和注射后脊髓12周 (图2).使用显微镜 (Axiovert 100 M), 在肌肉组织和脊髓运动神经元中检测到绿色荧光信号, 通过 GFP 的共定位和运动神经元标记胆碱乙酰转移酶 (聊天) 治疗后10周, 当小鼠开始显示疾病表现 (图 2)。
使用相同剂量方案, SBMA 小鼠随机接受 miR-298 或模拟7周的年龄通过尾静脉注射进行生化分析和功能表征。注射后, 每周体重和行为评估长达40周的年龄。qRT PCR 分析表明, miR-298 治疗降低了受影响的组织中突变 AR 的水平 (图 3), 增加了体重和改善的运动性能 (图 4) 从注射后10周开始。
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/55724/55724fig1.jpg"> 图 1: 研究设计示意图.为提高 miR-298在体内的表达水平, 我们注射 SBMA 小鼠 (A) 双启动子 AAV 载体, 表达 GFP, 或者 miR-298 或模拟。(B) 小鼠在7周的年龄 (症状前阶段) 通过一次无尾注射注入。SBMA 小鼠在不同时间点的组织分布分析 (绿色) 收集脊髓和四头肌肌肉。对 SBMA 小鼠进行了16周的生化分析 (红色) 治疗和牺牲。体重和行为分析每周进行40周的功能表征 (蓝色)。<a href="https://cloudflare.jove.com/files/ftp_upload/55724/55724fig1large.jpg" target="_blank">请单击此处查看此图的较大版本.</a>
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/55724/55724fig2.jpg"> 图 2: 小鼠 AAV9-miR-298 交付.使用这里描述的方法, 老鼠接受了 AAV9-miR-298-GFP 或 AAV9-mock-GFP 通过静脉注射。注射后24、8、12周从腰椎脊髓和股四头肌中收集 miRNA。qRT PCR 对 miR-298 (A) 股四头肌 (n = 5) (B) 腰椎脊髓 (n = 5, P < 0.01) 的表达水平进行了估计。所有的数据都是按标准误差表示的。在治疗后10周内, AAV 载体的广泛转导通过荧光蛋白 (C) 四头肌 (原放大倍数, 10X) 的染色定位证实。鳞片棒 = 100 µm) 和 (D) 腰脊髓运动神经元 (原放大倍数, 40X。缩放条 = 10 µm (绿色), 聊天 (红色) 和 DAPI (蓝色)。图已从 10.1038/mt 2016.13 修改。14<a href="https://cloudflare.jove.com/files/ftp_upload/55724/55724fig2large.jpg" target="_blank">请单击此处查看此图的较大版本.</a>
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/55724/55724fig3.jpg"> 图 3: 小鼠脊髓和股四头肌中 MiRNA-298 过表达 downregulates 突变 AR.qRT PCR 对 (A) 腰椎脊髓和 (B) AAV9-miR-298-GFP 或 AAV9-mock-GFP 治疗的股四头肌的 AR mRNA 表达水平进行了估计。转录水平被规范化到 snoRNA202 (每治疗 5)。* p < 0.05, ** p < 0.01。所有数据都以 "标准错误" 的方式报告。图已从 10.1038/mt 2016.13 修改。14
<img alt="Figure 4" class="xfigimg" src="/files/ftp_upload/55724/55724fig4.jpg"> 图 4: MiR-298 过度表达改善了运动功能, 减少了体重损失.行为评估每周进行一次 (w), 在5周到40之间。小鼠体重 (左) 和挂线 (右) 性能 (每组 15)。所有数据都以 "标准错误" 的方式报告。图已从 10.1038/mt 2016.13 修改。14

Watch this Scientific Journal Video about Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents at JoVE.com

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

在这里, 我们描述了 microRNA 使用重组腺相关病毒9型在小鼠神经肌肉疾病模型中的交付。小鼠的单个外围管理导致肌肉和运动神经元的持续 miRNA 过度表达, 为研究 miRNA 功能和体内的治疗潜力提供了机会。

重组腺相关病毒9型 MicroRNA 系统分娩治疗啮齿动物神经肌肉疾病

RNA interference via the endogenous miRNA pathway regulates gene expression by controlling protein synthesis through post-transcriptional gene silencing. ...

systemic-delivery-microrna-using-recombinant-adeno-associated-virus

Research

JoVE Journal

Genetics

7.6K 次观看.  National Institutes of Health. 在这里, 我们描述了 microRNA 使用重组腺相关病毒9型在小鼠神经肌肉疾病模型中的交付。小鼠的单个外围管理导致肌肉和运动神经元的持续 miRNA 过度表达, 为研究 miRNA 功能和体内的治疗潜力提供了机会。

视频: Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Despite the protective role that blood brain barrier plays in shielding the brain, it limits the access to the central nervous system (CNS) which most often results in failure of potential therapeutics designed for neurodegenerative disorders 1,2. Neurodegenerative diseases such as Spinal Muscular Atrophy (SMA), in which the lower motor neurons are affected, can benefit greatly from introducing the therapeutic agents into the CNS. The purpose of this video is to demonstrate two different injection paradigms to deliver therapeutic materials into neonatal mice soon after birth. One of these methods is injecting directly into cerebral lateral ventricles (Intracerebroventricular) which results in delivery of materials into the CNS through the cerebrospinal fluid 3,4. The second method is a temporal vein injection (intravenous) that can introduce different therapeutics into the circulatory system, leading to systemic delivery including the CNS 5. Widespread transduction of the CNS is achievable if an appropriate viral vector and viral serotype is utilized. Visualization and utilization of the temporal vein for injection is feasible up to postnatal day 6. However, if the delivered material is intended to reach the CNS, these injections should take place while the blood brain barrier is more permeable due to its immature status, preferably prior to postnatal day 2. The fully developed blood brain barrier greatly limits the effectiveness of intravenous delivery. Both delivery systems are simple and effective once the surgical aptitude is achieved. They do not require any extensive surgical devices and can be performed by a single person. However, these techniques are not without challenges. The small size of postnatal day 2 pups and the subsequent small target areas can make the injections difficult to perform and initially challenging to replicate.

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

This article demonstrates two very different methods of injection: 1) into the brain (intracerebroventricular) and 2) systemic (intravenous) to introduce the therapeutic agents into the central nervous system of neonatal mice.

交付的治疗药物通过侧脑室（ICV）和静脉（IV）注射液在小鼠

Despite the protective role that blood brain barrier plays in shielding the brain, it limits the access to the central nervous system (CNS) which most ...

科研

医学

使用球后注射技术对小鼠进行有效的全身递送

Systemic Treatment for Postnatal, Juvenile, and Runted Adult Mice by Retrobulbar Sinus Injection

While tail vein injections are frequently used as a systemic route of delivery in adult mice, retrobulbar injections are an alternative method for systemic delivery with fewer limitations. First, tail vein injections (TVIs) are limited to adult mice where the size of the tail vein is suitable for access. Being restricted to treating adult mice can be problematic when dealing with mouse models that do not survive to adulthood. Second, TVIs are not feasible for mouse models with growth retardation phenotypes where the mice never achieve the size of adult wildtype mice. Therefore, retrobulbar injections can be successfully used to treat both young and small adult mice. Lastly, retrobulbar injections are performed under anesthesia, which is less stressful on the mice than TVIs that are commonly performed without anesthesia. This article presents a protocol and detailed instructions for retrobulbar injections that can be used for systemic delivery to small and young mice.

作者聚焦:通过在小鼠模型中进行球后注射克服有机酸血症基因治疗的挑战

This article provides a protocol and an accompanying video for the retrobulbar sinus injection of up to a total volume of 150 &#181;L for postnatal, juvenile, and runted adult mice. This procedure is particularly well suited for the injection of small mice (15 g) when tail vein injection is not feasible.

球后窦注射对出生后、幼年和发育成年小鼠的全身治疗

While tail vein injections are frequently used as a systemic route of delivery in adult mice, retrobulbar injections are an alternative method for ...

遗传学

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Diseases affecting the integrity of spinal cord motor neurons are amongst the most debilitating neurological conditions. Over the last decades, the development of several animal models of these neuromuscular disorders has provided the scientific community with different therapeutic scenarios aimed at delaying or reversing the progression of these conditions. By taking advantage of the retrograde machinery of neurons, one of these approaches has been to target skeletal muscles in order to shuttle therapeutic genes into corresponding spinal cord motor neurons. Although once promising, the success of such gene delivery approach has been hampered by the sub-optimal number of transduced motor neurons it has so far shown to yield. Motor end plates (MEPs) are highly specialized regions on the skeletal musculature that are in direct synaptic contact to the spinal cord &#945; motor neurons. In this regard, it is important to note that, so far, the efforts to retrogradely transfer genes into motor neurons were made without reference to the location of the MEP region in the targeted muscles. Here, we describe a simple protocol 1) to reveal the exact location of the MEPs on the surface of skeletal muscles and 2) to use this information to guide the intramuscular delivery and subsequent optimal retrograde transport of retrograde tracers into motor neurons. We hope to utilize the results from these tracing experiments in further studies into investigating retrograde transport of therapeutic genes to spinal cord motor neurons through the targeting of MEPs.

The efficacy of intramuscular uptake and retrograde transport of molecules to corresponding motor neurons depends on the location of the injection sites with respect to the motor end plates (MEPs). Here, we describe how to locate MEPs on skeletal muscles to optimise retrograde transport of tracers into motor neurons.

肌肉注射沿运动终板:微创方法来接送示踪剂直接为运动神经元

Diseases affecting the integrity of spinal cord motor neurons are amongst the most debilitating neurological conditions. Over the last decades, the ...

神经科学

Subpial Adeno-associated Virus 9 (AAV9) Vector Delivery in Adult Mice

The successful development of a subpial adeno-associated virus 9 (AAV9) vector delivery technique in adult rats and pigs has been reported on previously. Using subpially-placed polyethylene catheters (PE-10 or PE-5) for AAV9 delivery, potent transgene expression through the spinal parenchyma (white and gray matter) in subpially-injected spinal segments has been demonstrated. Because of the wide range of transgenic mouse models of neurodegenerative diseases, there is a strong desire for the development of a potent central nervous system (CNS)-targeted vector delivery technique in adult mice. Accordingly, the present study describes the development of a spinal subpial vector delivery device and technique to permit safe and effective spinal AAV9 delivery in adult C57BL/6J mice. In spinally immobilized and anesthetized mice, the pia mater (cervical 1 and lumbar 1-2 spinal segmental level) was incised with a sharp 34 G needle using an XYZ manipulator. A second XYZ manipulator was then used to advance a blunt 36G needle into the lumbar and/or cervical subpial space. The AAV9 vector (3-5 &#181;L; 1.2 x 1013 genome copies (gc)) encoding green fluorescent protein (GFP) was then injected subpially. After injections, neurological function (motor and sensory) was assessed periodically, and animals were perfusion-fixed 14 days after AAV9 delivery with 4% paraformaldehyde. Analysis of horizontal or transverse spinal cord sections showed transgene expression throughout the entire spinal cord, in both gray and white matter. In addition, intense retrogradely-mediated GFP expression was seen in the descending motor axons and neurons in the motor cortex, nucleus ruber, and formatio reticularis. No neurological dysfunction was noted in any animals. These data show that the subpial vector delivery technique can successfully be used in adult mice, without causing procedure-related spinal cord injury, and is associated with highly potent transgene expression throughout the spinal neuraxis.

Subpial Adeno-associated Virus 9 AAV9 Vector Delivery in Adult Mice

The goal of the present study was to develop and validate the potency and safety of spinal adeno-associated virus 9 (AAV9)-mediated gene delivery by using a novel subpial gene delivery technique in adult mice.

在成年小鼠中的亚型腺相关病毒9（AAV9）载体递送

The successful development of a subpial adeno-associated virus 9 (AAV9) vector delivery technique in adult rats and pigs has been reported on previously. ...

Methods and Tips for Intravenous Administration of Adeno-associated Virus to Rats and Evaluation of Central Nervous System Transduction

Adeno-associated virus (AAV) vectors are a key reagent in the neurosciences for clustered regularly interspaced short palindromic repeats (CRISPR), optogenetics, cre-lox targeting, etc. The purpose of this manuscript is to aid the investigator attempting expansive central nervous system (CNS) gene transfer in the rat via tail vein injection of AAV. Wide-scale expression is relevant for conditions with widespread pathology, and a rat model is significant due to its greater size and physiologic similarities to humans compared to mice. In this example application, a wide-scale neuronal transduction is used to mimic a neurodegenerative disease that affects the entire spinal cord, amyotrophic lateral sclerosis (ALS). The efficient wide-scale CNS transduction can also be used to deliver therapeutic protein factors in pre-clinical studies. After a post-injection expression interval of several weeks, the effects of the transduction are evaluated. For a green fluorescent protein (GFP) control vector, the amount of GFP in the cerebellum is estimated quickly and reliably by a basic imaging program. For motor disease phenotypes that are induced by the ALS related protein transactive response DNA-binding protein of 43 kDa (TDP-43), the deficits are scored by escape reflex and rotarod. Beyond disease modeling and gene therapy, there are diverse potential applications for the wide-scale gene targeting described here. The expanded use of this method will aid in expediting hypothesis testing in the neurosciences and neurogenetics.

Methods for a wide-scale central nervous system gene delivery in the rat are covered. In this example, the purpose is to mimic a disease that affects the entire spinal cord. The widespread transduction can be used to deliver a therapeutic protein to the CNS from a one-time, peripheral administration.

腺相关病毒对大鼠的静脉管理方法和技巧及中枢神经系统转导的评价

Adeno-associated virus (AAV) vectors are a key reagent in the neurosciences for clustered regularly interspaced short palindromic repeats (CRISPR), ...

Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice

Intrathecal (IT) injection of adeno-associated virus (AAV) has drawn considerable interest in CNS gene therapy by virtue of its safety, noninvasiveness, and excellent transduction efficacy in the CNS.&#160;Previous studies have demonstrated the therapeutic potency of AAV-delivered gene therapy in neurodegenerative disorders by IT administration. However, high rates of unpredictable failure due to the technical limitation of IT administration in small animals have been reported. Here, we established a scoring system to indicate the success extent of lumbar puncture in small animals by adding 1% lidocaine hydrochloride into the injection solution. We further show that the extent of transient weakness following injection can predict the transduction efficiency of AAV. Thus, this IT injection method can be used to optimize therapeutic trials in mouse models of CNS diseases that afflict wide regions of the CNS.

Here we present a direct intrathecal injection technique using 1% lidocaine hydrochloride in a viral solution to ensure efficient adeno-associated virus delivery to small animals and establish a scoring system to predict transduction efficiency in the central nervous system according to the degree of transient weakness induced by lidocaine.

重组腺相关病毒在成年小鼠中的直接注射

Intrathecal (IT) injection of adeno-associated virus (AAV) has drawn considerable interest in CNS gene therapy by virtue of its safety, noninvasiveness, ...

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

The clustered, regularly interspaced, short, palindromic repeat (CRISPR) system has greatly facilitated genome engineering in both cultured cells and living organisms from a wide variety of species. The CRISPR technology has also been explored as novel therapeutics for a number of human diseases. Proof-of-concept data are highly encouraging as exemplified by recent studies that demonstrate the feasibility and efficacy of gene editing-based therapeutic approach for Duchenne muscular dystrophy (DMD) using a murine model. In particular, intravenous and intraperitoneal injection of the recombinant adeno-associated virus (rAAV) serotype rh.74 (rAAVrh.74) has enabled efficient cardiac delivery of the Staphylococcus aureus CRISPR-associated protein 9 (SaCas9) and two guide RNAs (gRNA) to delete a genomic region with a mutant codon in exon 23 of mouse Dmd gene. This same approach can also be used to knock out the gene-of-interest and study their cardiac function in postnatal mice when the gRNA is designed to target the coding region of the gene. In this protocol, we show in detail how to engineer rAAVrh.74-CRISPR vector and how to achieve highly efficient cardiac delivery in neonatal mice.

Here we provide a detailed protocol to carry out in vivo cardiac gene editing in mice using recombinant Adeno-Associated Virus(rAAV)-mediated delivery of CRISPR. This protocol offers a promising therapeutic strategy to treat dystrophic cardiomyopathy in Duchenne muscular dystrophy and can be used to generate cardiac-specific knockout in postnatal mice.

腺相关病毒介导的 CRISPR 在小鼠心脏基因编辑中的传递

The clustered, regularly interspaced, short, palindromic repeat (CRISPR) system has greatly facilitated genome engineering in both cultured cells and ...

Intravenous Injections in Neonatal Mice

Intravenous injection is a clinically applicable manner to deliver therapeutics. For adult rodents and larger animals, intravenous injections are technically feasible and routine. However, some mouse models can have early onset of disease with a rapid progression that makes administration of potential therapies difficult. The temporal (or facial) vein is just anterior to the ear bud in mice and is clearly visible for the first two days after birth on either side of the head using a dissecting microscope. During this window, the temporal vein can be injected with volumes up to 50 &#956;l. The injection is safe and well tolerated by both the pups and the dams. A typical injection procedure is completed within 1-2 min, after which the pup is returned to the home cage. By the third postnatal day the vein is difficult to visualize and the injection procedure becomes technically unreliable. This technique has been used for delivery of adeno-associated virus (AAV) vectors, which in turn can provide almost body-wide, stable transgene expression for the life of the animal depending on the viral serotype chosen.

Animal models of pediatric disease can experience early onset and aggressive disease progression. Clinically relevant therapy delivery to young mouse models can be technically difficult. This protocol describes a non-invasive intravenous injection method for newborn mice within the first two postnatal days of life.

重组腺相关病毒9型 MicroRNA 系统分娩治疗啮齿动物神经肌肉疾病

摘要

探索更多视频

此视频中的章节

交付的治疗药物通过侧脑室（ICV）和静脉（IV）注射液在小鼠

球后窦注射对出生后、幼年和发育成年小鼠的全身治疗

球后窦注射对出生后、幼年和发育成年小鼠的全身治疗

球后窦注射对出生后、幼年和发育成年小鼠的全身治疗

肌肉注射沿运动终板:微创方法来接送示踪剂直接为运动神经元

在成年小鼠中的亚型腺相关病毒9（AAV9）载体递送

腺相关病毒对大鼠的静脉管理方法和技巧及中枢神经系统转导的评价

重组腺相关病毒在成年小鼠中的直接注射

腺相关病毒介导的 CRISPR 在小鼠心脏基因编辑中的传递

在新生小鼠静脉注射